Antibiotic Induced Diarrhoea & Colitis in Orthopaedic in-Patients

  • R. L. Parsons
  • Jacqueline Salfield
  • J. P. Beavis
Part of the Chemotherapy book series (CT, volume 4)


2 patients undergoing total hip replacement by the orthopaedic dept. @ Guys group of hospitals received prophylactic lincomycin during the procedure, (1.2). Subsequently, they developed pseudomembranous colitis. Since lincomycin is an effective antistaphylo-coccal antibiotic that penetrates both normal & infected bone (3.4), the unexpected frequency of this side effect, which was not initially recognised as being due to the drug, led us to question the wisdom of continuing its routine use for prophylactic cover during this procedure. Subsequent studies (5) showed that cephradine was not a satisfactory alternative to lincomycin in this situation. In view of these problems and the subsequent crop of case reports that appeared in the literature at the end of 1973 (6) and early in 1974 (7–11), we decided to conduct a retrospective survey of the incidence of diarrhoea & colitis in orthopaedic in-patients at Guy’s durin the 19 months (January 1973 — August 1974) that pseudomembranous colitis was becoming recognised in the U.K. as being associated with lincomycin & clindamycin.


Pseudomembranous Colitis Subsequent Crop Satisfactory Alternative Staphylococcal Sepsis Unexpected Frequency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    PARSONS, R.L., BEAVIS, J.P., HOSSACK, G.M. & PADDOCK, G.M. Lincomycin concentrations during total hip replacement. British Journal of Clinical Pharmac. 2, in press (1975)Google Scholar
  2. (2).
    PARSONS, R.L., BEAVIS, J.P., PADDOCK, G.M. & HOSSACK, G.M. Lincomycin concentrations during total hip replacement. Proceedings of the 9th International Congress of Chemotherapy. in press (1975)Google Scholar
  3. (3).
    GRADY, D.C. & STERN, K.F. Penetration of lincomycin into hone. Antimicrobial Agents & chemotherapy, 5, 201–205. (1965)Google Scholar
  4. (4).
    NORDEN, C.W. & KENNEDY, E. Experimental osteomyelitis. II. Therapeutic trials and measurement of antibiotic levels in hone. Journal of Infectious diseases. 124, 565–571. (1971)PubMedCrossRefGoogle Scholar
  5. (5).
    PARSONS, R.L., BEAVIS, J.P., PADDOCK, G.M. & HOSSACK G.M. Cephradine Bone concentrations during total hip replacement. Proceedings of the 9th International Congress of Chemotherapy. in press (1975)Google Scholar
  6. (6).
    SCOTT, A.J., NICHOLSON, G.I. & KERR, A.R. Lincomycin as a cause of pseudomembranous colitis. Lancet. 2, 1232–1234.(1973)PubMedCrossRefGoogle Scholar
  7. (7).
    DYCK, W.P., VITERI, A.L. & HOWARD, P.H. Lincomycin, clindamycin & colitis. Lancet. 1, 272–273 (1974).PubMedCrossRefGoogle Scholar
  8. (8).
    PITTMAN, F.E., PITTMAN, J.C. & HUMPHREY, CD. Lincomycin and pseudomembranous colitis. Lancet. 1, 451–452 (1974)PubMedCrossRefGoogle Scholar
  9. (9).
    SISSONS, J.G.P., BOULTON-JONES, J.M. & PETERS D.K. Clindamycin and pseudomembranous colitis. Lancet. 1, 172. (1974)CrossRefGoogle Scholar
  10. (10).
    TEMPERLEY, J.M. Lincomycin, clindamycin & colitis. Lancet. 1, 221 (1974)Google Scholar
  11. (11).
    WELLS, R.F., COHEN, L.E. & McHEILL, C.J. Clindamycin & pseudomembranous colitis. Lancet. 1, 66. (1974)PubMedCrossRefGoogle Scholar
  12. (12).
    SMITH H.T. Pseudomembranous enterocolitis Minnesota Medicine. 50, 405–412. (1967)Google Scholar
  13. (13).
    FITZGERALD, R.H., PETERSON, F.A., WASHINGTON, J.A. & Van SCOY, R.E. Bacterial colonization of wounds and sepsis in total hip arthroplasty. J. hone & joint Surg. 55-A, 1242–1250 (1973)Google Scholar
  14. (14).
    REINER, L., SCHLESINGER, M.J. & MILLER, G.M. Pseudomemhranous colitis following aureomycin and chloramphenicol. A.M.A. Arch. Path. 54, 54–67. (1952)Google Scholar
  15. (15).
    BASS, J.W., CROWLEY, D.W., STEELE, R.W., YOUNG, F. S.H. & HARDEN, L.B. Adverse effects of orally administered ampicillin. J. Pediat. 83, 106–108 (1973)PubMedCrossRefGoogle Scholar
  16. (16).
    DEHANN, R.M., SCELENBERG, M.A., VANDEN BOSCH, W.D. & MAILE, M.H. Clindamycin palmitate in healthy men: General tolerance and effect on stools. Current Therapeutics & Research. 14, 81–90. (1972)Google Scholar
  17. (17).
    DUNCAN, I.B.R. & JEANS, B. Lincomycin in hospital practice. Can. Med. Ass. J. 93, 685–691 (1965)PubMedGoogle Scholar
  18. (18).
    McGEHEE, R.F., Jr., SMITH, C.B., WILCOX, C. & FINLAND, M. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and excretion of lincomycin and clinimycin. Amer. J. Med. Sci. 256, 279–292. (1968)PubMedCrossRefGoogle Scholar
  19. (19).
    PRICE, D. J., O’GRADY, F. W., SHOOTER, R. A. & WEAVER, P. C. Trial of Phenoxymethylpenicillin, phenethicillin and lincomycin in treatment of staphylococcal sepsis in a casualty department. Brit. med. J. 3, 407–409. (1968)PubMedCrossRefGoogle Scholar
  20. (20).
    TEDESCO, F.J., BARTON, R.W., & ALPERS, D.H. Clindamycin associated colitis. Annals of Int. Med. 81, 429–433 (1974)Google Scholar
  21. (21).
    FINNEY, J. M.T. Gastroenterostomy for cicatrizing ulcer of the pylorus. Bull. Johns Hopkins Hosp. 4, 53–55 (1893)Google Scholar
  22. (22).
    BURBIGE, E.J. & MILLIGAN, Pseudomembranous colitis. Association with antibiotics and Therapy with Cholestyramine. J.A.M.A. 231, 1157–115S (1975)PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • R. L. Parsons
    • 1
  • Jacqueline Salfield
    • 1
  • J. P. Beavis
    • 1
  1. 1.Dept. Clinical Pharmacology & OrthopaedicsGuy’s Hospital Medical SchoolLondonUK

Personalised recommendations